SSY Group Profit Halves as Revenue and Margins Slide in Challenging 2025

SSY Group ( (HK:2005) ) has issued an announcement.

SSY Group reported a sharp deterioration in 2025 results as shrinking demand, tighter policies and intensifying competition hit its pharmaceutical business, with revenue falling 27.8% to about HK$4.17 billion and net profit dropping 55.6% to HK$471 million. The revenue decline was broad-based across key infusion and injection product lines, gross margin contracted by 8.8 percentage points to 41.6%, and the board cut the full-year dividend by 54.3% to HK$0.08 per share, underscoring the earnings pressure and a more cautious capital return stance toward shareholders.

Management responded by emphasizing an integrated “bulk pharmaceuticals + preparations” strategy and efforts to reinforce dominant products amid a rapidly evolving drug market, though the data highlight that SSY is facing its most severe operational headwinds in recent years. The results signal a tougher competitive and regulatory landscape for hospital-use infusion and injectable drugs in China, with implications for margin sustainability and the group’s ability to restore growth and maintain investor returns in the near term.

The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited is a Cayman Islands-incorporated pharmaceutical group listed in Hong Kong, focusing on intravenous infusion solutions, bulk pharmaceuticals, ampoule injections and oral preparations. Its product portfolio is geared toward hospital and medical market demand in China and related markets, with a core strategy of integrating bulk drug production with finished dosage forms.

Average Trading Volume: 8,346,836

Technical Sentiment Signal: Sell

Current Market Cap: HK$7.23B

For an in-depth examination of 2005 stock, go to TipRanks’ Overview page.